文献速递真菌感染

非中性粒细胞减少肺部曲霉病患者支气管肺泡灌洗液与血浆中的五聚蛋白3

Pentraxin 3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with pulmonary aspergillosis.
PubMed 文献 · Clin Microbiol Infect · 2018-06-28

本研究检测非中性粒细胞减少、初始怀疑肺部曲霉病患者支气管肺泡灌洗液(BALF,n=211)和血浆(n=307)中的五聚蛋白3(PTX3),其中112例确诊肺部曲霉病。曲霉病组BALF与血浆PTX3中位数均高于非曲霉病对照组,作者认为BALF和血浆PTX3可能作为鉴别肺部曲霉病与其他疾病的生物标志物。

要点

  • 曲霉病组BALF PTX3中位数6.97 ng/mL,高于非曲霉病组的1.26 ng/mL
  • BALF PTX3阈值1.9 ng/mL时,敏感度86.3%、特异度82.5%
  • 血浆PTX3阈值2.3 ng/mL时,敏感度79.8%、特异度72.1%

核心结论

  • BALF和血浆PTX3可能作为非中性粒细胞减少患者中鉴别肺部曲霉病与社区获得性肺炎、肺癌、肺隐球菌病等其他疾病的生物标志物。

研究设计与样本

  • 研究采集初始怀疑肺部曲霉病患者的BALF样本211份和血浆样本307份,其中112例确诊肺部曲霉病(含BALF样本51份、血浆样本89份),并收集健康对照血浆样本30份。
  • 确诊的肺部曲霉病病例分为侵袭性肺曲霉病(IPA)、亚急性侵袭性曲霉病(SAIA)和慢性肺曲霉病(CPA);其余病例为非曲霉病对照,诊断为社区获得性肺炎(CAP)、肺癌和肺隐球菌病。

主要发现

  • 曲霉病组BALF PTX3中位数(IQR)为6.97(2.91-13.51)ng/mL,显著高于非曲霉病组的1.26(0.76-1.76)ng/mL。
  • 曲霉病组血浆PTX3中位数(IQR)为7.10(3.36-9.53)ng/mL,显著高于非曲霉病组的1.57(0.86-2.35)ng/mL和健康对照的1.10(0.49-1.51)ng/mL。

关键数值与推荐

  • BALF PTX3阈值设为1.9 ng/mL时,对曲霉病的敏感度为86.3%(95%CI 83.8-88.4%),特异度为82.5%(95%CI 79.7-85.0%)。
  • 血浆PTX3阈值设为2.3 ng/mL时,敏感度为79.8%(95%CI 70.1-81.2%),特异度为72.1%(95%CI 69.5-74.5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Pentraxin 3 (PTX3) contributes to resistance to Aspergillus infections. This study aimed to evaluate the presence of PTX3 in bronchoalveolar lavage fluid (BALF) and plasma in non-neutropenic patients with pulmonary aspergillosis. METHODS: BALF (n = 211) and plasma samples (n = 307) were collected from patients initially suspected of having pulmonary aspergillosis. Among these, 112 cases (51 BALF samples and 89 plasma samples) were proven to be pulmonary aspergillosis. These cases were classified as invasive pulmonary aspergillosis (IPA), subacute invasive aspergillosis (SAIA) and chronic pulmonary aspergillosis (CPA). The remaining cases were non-aspergillosis controls and were diagnosed with community-acquired pneumonia (CAP), lung cancer and pulmonary cryptococcosis. Plasma samples from healthy controls (n = 30) were also collected. RESULTS: The median (interquartile range, IQR) BALF PTX3 for aspergillosis cases was significantly higher than for non-aspergillosis cases: 6.97 (2.91-13.51) ng/mL versus 1.26 (0.76-1.76) ng/mL. When the PTX3 threshold was set at 1.9 ng/mL, sensitivity and specificity of BALF PTX3 for aspergillosis were 86.3% (95%CI 83.8-88.4%) and 82.5% (95%CI 79.7-85.0%), respectively. The median (IQR) plasma PTX3 for aspergillosis cases was significantly higher than for non-aspergillosis cases and healthy controls: 7.10 (3.36-9.53) ng/mL versus 1.57 (0.86-2.35) ng/mL versus 1.10 (0.49-1.51) ng/mL. With a PTX3 threshold of 2.3 ng/mL, sensitivity and specificity were 79.8% (95%CI 70.1-81.2%) and 72.1% (95%CI 69.5-74.5%) respectively. CONCLUSIONS: BALF and plasma PTX3 may be biomarkers for differentiating aspergillosis from other conditions such as CAP, lung cancer, and pulmonary cryptococcosis in non-neutropenic patients.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Li H, Liu L, Zhou W, et al. Pentraxin 3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with pulmonary aspergillosis. Clin Microbiol Infect. 2018. PMID: 29964232. doi:10.1016/j.cmi.2018.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。